A Review on Diabetic Peripheral Neuropathy

Jasaswi Ray*, Chinmaya Keshari Sahoo, Rajashree Mohanty, Rakesh Sahoo, Rajashree Dalai

Department of Pharmacy, College of Pharmaceutical Sciences, Bidyaniketan, Puri-Konark marine drive Road, Puri, Odisha-752002

INTRODUCTION

Diabetic neuropathy comprises the disorder of peripheral nerve in people suffering with diabetes mellitus. Diabetes has become one of the largest global health care problems of the 21st century. It was estimated that around 415 million people worldwide suffered from diabetes in the year 2015, and these value are expected to increase to 624 million people by the year 2040. Almost 50% of the people suffering through diabetes are expected to develop Diabetic peripheral neuropathy. Diabetic peripheral neuropathy is defined as "presence of symptoms and/or sign of peripheral nerve dysfunction in people with diabetes after exclusion of other causes". Diabetic peripheral neuropathy has devastating effect in the day to day life of the patient. Patient with Diabetic neuropathy repay firstly pain in the lower limbs of their body. This pain may be of different types like sensation of burning, sensation of electric shock, prickling of needle etc. In some cases patient also suffer through loss of sensation. DPN significantly affects the quality of life of the patient and management of wealth (due to disease). Once diagnosed DPN leads to new challenges in the patient management.

EPIDEMIOLOGY

The epidemiology and natural history of patients are difficult to describe because of various clinical diagnostic criteria, variable selection of patients (patients with or without pain) and wide ranging physiological techniques. The EURODIAB complications study identified a prevalence of 28% for DPN at baseline with glycemic control and duration of diabetes being major determinants similar data was observed in the Diabetes Control and Complications Trial (DCCT)*. In a study of 4400 patients, the prevalence of DPN was found to be about 75% of newly diagnosed diabetes increasing to be 45% after 25 years of diabetes.

RISK FACTOR FOR DPN

The risk factor for DPN was determined by EURODIAB on 1100 people with type 1 diabetes followed over a period of 7.5 years. These risk factor was similar to macrovascular disease like hypertension, smoking, increased lipid levels, duration of diabetes and body mass index. It was seen that neuropathic pain is also associated with other diseases like peripheral arterial disease (non-diabetic subject). So this is an important factor in diagnosis and treatment of neuropathic pain.

CLINICAL FEATURES/SYMPTOMS

The signs of diabetic neuropathy are variable. The neuropathic pain includes deep, aching pain with superimposed burning and stabbing pain. From a survey it was found that between 25% and 39% of patients may lack adequate treatment for their pain leading negative impact on quality of life. The pain has been reported to in with general activity, mood, mobility, work, social relations, sleep, leisure activities, walking ability and enjoyment of life.

ETOLOGY

Although exact cause of diabetic neuropathy is not known but it is thought to be caused due to nerve dysfunction and

KEYWORDS: DPN, hyperglycemia, depression, lidocaine
cell break and that results from oxidative stress and inflammation. Various health condition like hyperglycemia, dyslipidemia and insulin resistance all contribute towards dysfunction of various metabolic pathways like polyol pathway that sum up to cause the excess formation of mitochondrial and cytotoxic reactive oxygen species. These reactive oxygen species cause the injury to the axon of the nerve of the PNS hence leading to DPN. Multiple neurotransmitter also affect the pain pathway.

**PATHOPHYSIOLOGY**

The development of DPN is multifactorial. The harmful metabolic effects of chronic hyperglycemia and effect of ischemia to the peripheral nerves are supposed to be the two mechanisms leading to dysfunction and damage. The pathophysiological effects of hyperglycemia are wide variety and include: activation of polyol pathway, generation of reactive oxygen species (ROS) (Oxidative stress), and reactive nitrogen species (Nitrosative stress) and accumulation of advanced glycation end products (AGE). Excess glucose in the body is metabolized by polyol or sorbitol pathway. In this pathway glucose is reduced to sorbitol by the enzyme aldose reductase, (rate limiting step) before being oxidized by sorbitol dehydrogenase to fructose which is a potent glycatying agent. The intracellular accumulation of sorbitol leads to reduction in nerve myoinositol and taurine and disruption of Na⁺ / k⁺ ATPase membrane activity leading to accumulation of sodium in nerve, dysfunction of axon and structural damage the nerves. The basement membrane of endothelial cells becomes glycosylated due to glycation of free amino group of protein, lipids and nucleic acid with alteration in their molecular structure and function. This leads to impaired vasodilation. Additionally the accumulated AGEs bind to receptor of AGE on macrophages with production of inflammatory cytokines (IL-1), tumor necrosis factor, growth factor and adhesion molecules (VCAM-1). Another novel pathway that’s leads to complications of diabetes is activation of nuclear enzyme poly (ADP ribose) polymerase (PARP). Increased oxidative stress results in DNA damage and PARP 1 activation leading to cellular energy failure which is thought to be important in the pathogenesis of DPN.

**TREATMENT OF DPN**

The DPN represent a great therapeutic challenge in pharmacological aspects. As the exact pathophysiology of the disease is unknown. Hence it can’t be cured completely but it can be prevented as the pain can be reduced by the following three main principles: glycemic control, foot care and pain management. The glycemic control and foot care efforts are largely preventative. Lifestyle intervention including weight loss and physical activity may also be helpful in treatment of DPN. Pharmacological treatment is indicated. The American diabetes association recommends medication for the relief of pain. Some guidelines recommend the use of pharmacological treatments both approved and off-label to reduce pain and to improve quality of life in DPN patients. These treatments include antidepressant, anticonvulsant, analgesic, and topical medications. A wide variety of drugs used alone or in combination has been shown significantly reduce neuropathic pain.

Three different agents have regulated approval for the treatment of DPN i.e. Pregabalin, Duloxetine, and Tapentadol. Pregabalin was the first anticonvulsant to receive approval from the Food and Drug Administration (FDA) for the treatment of DPN and neuropathic pain after spinal cord injury. Pregabalin is also proposed to be the result of improved trafficking of α2-δ subunits with a consequent diminishes expression of function Ca 2+ channels. In addition to analgesic effects, Pregabalin present anxiolytic ability and it has a beneficial effect on sleep and quality of life. Therefore contributing to improve the general condition of patients. Side effects include dizziness, somnolence, peripheral oedema, headache and weight gain. Besides Pregabalin, Gabapentin is the only other anticonvulsant drug that is used for treatment of DPN. Some clinical trials have suggested that Gabapentin and Pregabalin present better analgesic efficiency than tricyclic antidepressants or opioids. Other important aspects of this drug include its tolerability and lack of serious toxicity.

**Antidepressants**

Anti-depressant represents the first-line of drug in DPN Management. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is rated level A for efficacy and is approved in the United States for the treatment of this condition. The analgesic efficacy of Duloxetine in the treatment of DPN is maintained over a 6 month period. Hence it is a preferred drug for the treatment of DPN. Side effects are nausea, somnolence and dizziness as side effects. Other TCA like Amitriptyline and nortriptyline are found to be effective in treatment of DPN. Most common side effects are postural hypotension, arrhythmias, congestive impairment, constipation and urinary retention. These side effects are more frequently observed after amitriptyline than nortriptyline treatment.

**Opioids**

Opioids are used as second or third line treatment of DPN. Opioids like morphine and tramadol can be used to lower DPN but they have some side effects like nausea, headache and somnolence. Tapentadol has been shown to be effective in management of different types of chronic pain, low back pain and DPN with a tolerable safety profile. Trials have reported reduction of at least 30% in pain intensity in about 50% of the patients that reserved Tapentadol.
Capsaicin Topical Cream

Use of topical products may lead to less possibility of adverse effects. In addition the possibilities of drug interaction are markedly reduced by the use of topical local treatments which represent good options for patients with multiple medical problems.42 The capsaicin cream has been shown to be effective in the treatment of neuropathic conditions 43 and is approved for topical relief of pain 42. There are some adverse effects linked with capsaicin cream which include itching, stinging, erythema, transient burning sensation and initial pain at the site of application which diminishes with repeated use.44,45

Lidocaine Patch

Lidocaine patches acts as peripheral analgesic with minimal systemic absorption and currently used with other analgesic drugs 44,46. Lidocaine acts as sodium channel blockers thereby counteracts the hyper excitability of peripheral nociceptors that contributes to neuropathic pain.34,44,47. Adverse effects are local irritation, contact dermatitis and itching.

Alpha Lipoic Acid

Alpha lipoic acid (ALA) acts as an antioxidant thereby it reduces oxidative stress, which is an important factors in pathophysiology of Diabetic neuropathy.34. Its antioxidant and anti-inflammatory actions may contribute to an all-round improvement of diabetic neuropathy symptoms.48. ALA has the least side effects among all the various other drugs used for treatment of DPN. The common side effects of ALA is nausea and vomiting.44

POPULATION STUDY

The most common and debilitating microvascular complication of diabetes is diabetic peripheral neuropathy (DPN), affecting 50-90% of people with diabetes 49. The major manifestations of DPN are painful (pDPN) and painless diabetic peripheral neuropathy. The explosion of diabetes, especially in the South East Asian (SEA) region will result in an increasing prevalence of both painful and painless diabetic peripheral neuropathy. In the United States (US) and Europe, pDPN is estimated to occur in up to one-third of all patients with diabetes 50,51,52,53,54. Although diabetes is an increasing problem in Asia 55,56,57 studies estimating the prevalence of pDPN are scarce. In a nationwide, observational study of approximately 4000 patients with type2 diabetes in Korea, the estimated pDPN prevalence was 14.4%, or 43.1% of patients with DPN 55. In Japan, 22.1% of 290 diabetic out patients were found to have pDPN 59.

Bangladesh

In a study from 2006, the prevalence of DPN was 19.7% in randomly selected patients with Type 2 Diabetes Mellitus (T2DM) aged 50±10.6 years and increased with age and duration of diabetes the prevalence increases.60. In a study from 2012 in the outpatient department the prevalence of DPN was 35% with was a cross sectional study of 140 patients.49. In another study of 400 patients, neuropathy was diagnosed from the medical records and a prevalence of 16.8% was established.61

India

A cross sectional study in 2013 was undertaken in North India in 586 participants of whom 18.4% were newly diagnosed (< 6 months) and 81.6% had known diabetes with a mean age of 57.1±9.7 years and mean duration of diabetes of 10.8±7.5 years with the help of Semmes-Weinstein monofilament (SWM) and vibration perception threshold (VPT).49. Similarly a study from South India with 1000 diabetic patients underwent biothesiometry and assessment of VPT, the prevalence was found to be 19.1%.62. A retrospective study from Goa of 3261 patients with T2DM established a prevalence of 16.3%.63. In another study of 1500 patients with young onset diabetes aged 34.68±23.23 years, the prevalence of advanced neuropathy, the prevalence was found to be 13.1%.64. In a retrospective study of 249 T2DM patients in a tertiary setting, a surprisingly low prevalence of 14.4% was established, but the method of diagnosing neuropathy was not disclosed.65. A study of 1319 T2DM patients from 4 centers across India, SWM insensitivity the prevalence was found to be 15%.66

Sri Lanka

In a study of 528 diabetic patients of which 191 were newly diagnosed patients, used Diabetic Neuropathy symptom (DNS) score to determine DPN relevance of 48.1%.49. Test on Toronto clinical scoring system (TCSS) the prevalence with known Diabetes was found to be 24%.67. A most recent study with taking 8401 people was done in a Diabetic centre in Jaffna established as DPN prevalence of 34.1%.68. In a further study of 1007 young Diabetic patients aged 36.6±11.17 years with diabetes duration of 4.8±4.2 years, using neurological symptoms the DPN relevance was found to be 30.7%.49

Thailand

In a retrospective study of 1110 (T1DM-6%, T2DM- 94%) diabetic patients from 37 primary health care clinics Indonesia the prevalence of DPN was found to be 34%.69. While in another study with 899 Thai T2DM patients underwent assessment with the SWM (Semmes-Weinstein monofilament) on seven areas of the foot and 15.9% were diagnosed with advanced neuropathy and deemed at high risk of foot ulceration.70. Similarly cross-sectional study of 438 diabetic patients from a tertiary care diabetes clinic, insensitivity to the SWM was found in 19.2%.71

Indonesia

A cross sectional study of 1785 people in Indonesia was done between 2008-2009 and the prevalence of DPN was found to be 67.1%.72. In similar studies from Surabaya assessed the medical records of 302 T2DM patients and found the prevalence of DPN to be 58.6%.73

CONCLUSION

DPN remains a common and disabling complication of diabetes. The treatment should be focused on identification of risk factors, implementation of diabetic foot care program, symptom relief to improve quality of life and patient education is the key. Approaches like gene therapy and targeted delivery of antioxidant therapy may in the future offer the best potential to reverse this common and disabling complication of diabetes. Approx 50% adult with diabetes will be affected by peripheral neuropathy in their lifetime, more diligent screening and management would be the key to reduce complications and health care burden associated with the disease.

REFERENCES

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137– 149. doi:10.1016/j.diabres.2013.11.002
2. Zhou H, Zhang W. Gene expression profiling reveals candidate biomarkers and probable molecular mechanism in Diabetic peripheral neuropathy. Diabetes, Metabolic Syndrome and
3. Knowledge, Barrett-Connor E, Feuer SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403.10.1056/NEJMoa012512 [PubMed: 11832527].

4. American Diabetes Association, American Academy of Neurology: Report recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988; 11:592–597.

5. Toeller M, Buyken AE, Heitkamp G, et al. Prevalence of chronic complications, metabolic control and nutritional intake in type 1 diabetes: comparison between different European regions. EURODIAB Complications Study Group. Horm Metab Res 1999; 31:680–685.

6. Shaker J, Stevens MJ. Updates on the management of diabetic polyneuropathies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011; 4:289-305 [PubMed: 11740.133.2032]

7. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Comp 1992; 6:49–57.

8. Tesfaye S, Chaturvedi N, Eaton SE, et al; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. Diabet Med 2005; 22:710–715.

9. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care. 2008; 31(Suppl 2):S255–S261.

10. Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D’Souza DN, et al. Duloxetine for the management of diabetic peripheral neuropathic pain evaluation of functional outcomes. Pain Med. 2008; 9:410–418.

11. Feldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron. 2017; 93(6):1296–1310.10.1016/j.neuron.2017.02.005 [PubMed: 28334605].

12. Sajic M. Mitochondrial dynamics in peripheral neuropathies. Antioxid Redox Sign. 2014; 21(4):601–620.10.1089/ars.2013.5822 [PubMed: 24386984].

13. Chokroverty S, Reyes MG, Rubino FA, et al. The syndrome of diabetic amyotrophy. Ann Neurol. 1977; 2:131.

14. Shaker J, Stevens MJ. Updates on the management of diabetic polyneuropathies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011; 4:289-305 [PubMed: 11740.133.2032]

15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:913–923.

16. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end products: a review. Antioxid Redox Signal. 2011; 14(18):813–826.10.1089/ars.2011.3802 [PubMed: 22083665].

17. Vinik AI, Erbas T, Park TS, Donofrio P, Cornblath D, Sachdeo R. A study of the use of carbacholamine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes MetabDisorder 2014; 13:62.10.1186/2252-6851-13-62.

18. Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36:2456–2465 [PubMed: 23970715].

19. Page N, Deluca J, Crowell K. Clinical inquiry: what medications are best for diabetic neuropathic pain? J Fam Pract 2012; 61:69–693 [PubMed: 23256101].

20. Harati Y, Gooch G, Sweney M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Slu CQ, Cadin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50:1842-1846 [PubMed: 9633738].

21. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44:1973–1988 [PubMed: 11719628].

22. Saarto T, Wiljen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2011; 82:1372–1373 [PubMed: 20543189].

23. Page N, Deluca J, Crowell K. Clinical inquiry: what medications are best for diabetic neuropathic pain? J Fam Pract 2012; 61:69–693 [PubMed: 23256101].

24. Afiflalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013; 16:27-40 [PubMed: 23340531].

25. Tesfaye S, Ounton SA, Callaghan BC. Painful diabetic neuropathy. BMJ 2014; 348:g1799 [PubMed: 24803311].

26. Freeman R. New and developing drugs for the treatment of neuropathic pain in diabetes. Curr Diab Rep 2013; 13:500-508 [PubMed: 23771401].

27. Peltier A, Gounon SA, Callaghan BC. Painful diabetic neuropathy. BMJ 2014; 348:g1799 [PubMed: 24803311].

28. Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: diagnosis and management. Neuroendocrinology 2013; 98:267-280 [PubMed: 24458095].
44. Zillich A, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol 2011; 13:143-159. doi: 10.1007/s11940-011-0153-7. [PubMed] [CrossRef] [Google Scholar]

45. Groninger H, Scheker RE. Topical capsaicin for neuropathic pain #255. J Palliat Med 2012; 15:946-947 [PMID: 22849599 DOI: 10.1186/jpjm.2012.9571]

46. Wolff RF, Bala MM, Westwood M, Kessels AG, Kleinj J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly 2010; 140:297-306 [PMID: 20458651]

47. Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine medicated plaster. TherClin Risk Manag 2014; 10:259-268 [PMID: 24790451 DOI: 10.2147/TCRM.S50844]

48. Patel N, Mishra V, Patel P, Dikshit RK. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes Metab Disord 2014; 13:62 [PMID: 24926454 DOI: 10.1186/s11940-013-013-0] [CrossRef] [Google Scholar]

49. Ahmunnadi H, Ponirakis G, Adnan Khan, Rayaz Ahmed Malik. Diabetic neuropathy and painful diabetic neuropathy: Cinderella complications in South East Asia 2018; [Research Article, S22195432]

50. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008; 9:660-674. doi: 10.1111/j.1533-0007.2008.00173.x [PubMed] [CrossRef]

51. S. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006; 29:1518-1522. doi: 10.2337/dc05-2228 [PubMed] [CrossRef]

52. Alleman CJ, Westerhout KY, Hensen M, et al. Humanistic and economic outcomes of painful diabetic peripheral neuropathy in Europe: A review of the literature. Diabetes Res Clin Pract. 2015; 109:215-225. doi: 10.1016/j.diabres.2015.04.031. [PubMed] [CrossRef] [Google Scholar]

53. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postoperative neuralgia, and less commonly studied neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine medicated plaster. TherClin Risk Manag 2014; 10:259-268 [PMID: 24790451 DOI: 10.2147/TCRM.S50844]

54. Gregg EW, Sorlie P, Paulose RM, et al. Macrovascular and microvascular complications at diagnosis in patients with young onset type 2 diabetes in India: CINDI 2. Indian J Endocrinol Metab 2015; 19:341-348. doi: 10.4103/0971-5304.156429. [PMC free article] [CrossRef]

55. Viswanathan V. Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes – an 11-year follow up study. Indian Heart J. 2014; 66:5-10.

56. Viswanathan V, Thomas N, Tandon N, Asirvatham A, Rajasekar S, Ramachandran A. Profile of diabetic foot complications and its associated complications – a multicentric study from India. J Assoc Physicians India. 2005; 53:933-6.

57. Katulanda P, Ranaasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr. 2012; 4:21.

58. Nitiyanant W, Chetthakul T, Sang AkP, Therakiatkumjorn C, Kunsuikmengrai K, Yeo JP. A survey study on diabetes management and complication status in primary care setting in Thailand. J Assoc Physicians India. 2007; 90:65-71.

59. Sattapath C, Potisat S, Jongsareejit S, Krainitichai U, Pooreesathian K. Prevalence of factors predisposing to foot complication and their relation to other risks. J Med Assoc Thai. 2012; 95:1013-20.

60. Kosachunhanun N, Tongprasert S, Rerkasem K. Diabetic foot problems in tertiary care diabetic clinic in Thailand. Int J Low Extrem Wounds. 2012; 11:124-7.

61. Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji D, Adnan Khan, Rayaz Ahmed Malik. Microvascular complications and their associated risk factors in type 2 diabetes mellitus. Diabetes Metab Syndr. 2017-2018; 297-306 [PMID: 20458651]

62. Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji D, Adnan Khan, Rayaz Ahmed Malik. Microvascular complications and their associated risk factors in type 2 diabetes mellitus. Diabetes Metab Syndr. 2017-2018; 297-306 [PMID: 20458651] [CrossRef] [Google Scholar]